Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

The Influence of Etoricoxib on Pain Control for Laparoscopic Cholecystectomy

A Meta-analysis of Randomized Controlled Trials

Qiu, Jin, PhD*; Xie, Mian, PhD*; Qu, Ronglan, PhD

Surgical Laparoscopy Endoscopy & Percutaneous Techniques: June 2019 - Volume 29 - Issue 3 - p 150–154
doi: 10.1097/SLE.0000000000000635
Review Articles
Buy

Introduction: The efficacy of etoricoxib on pain control for laparoscopic cholecystectomy remains controversial. We conduct a systematic review and meta-analysis to explore the impact of etoricoxib on pain intensity after laparoscopic cholecystectomy.

Materials and Methods: We searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through September 2018 for randomized controlled trials assessing the effect of etoricoxib versus placebo on pain management after laparoscopic cholecystectomy. This meta-analysis was performed using the random-effect model.

Results: Four randomized controlled trials involving 351 patients are included in the meta-analysis. Overall, compared with control group for laparoscopic cholecystectomy, etoricoxib has no important impact on pain scores within 4 hours [mean difference (MD)=−1.48; 95% confidence interval (CI)=−3.54 to 0.58; P=0.16] and 8 hours (MD=−0.65; 95% CI=−1.43 to 0.12; P=0.10), but can significantly decrease pain intensity within 12 hours (MD=−1.16; 95% CI=−1.93 to −0.38; P=0.003) and 24 hours (MD=−1.10; 95% CI=−1.98 to −0.22; P=0.01), as well as postoperative analgesic consumption (standard MD=−1.21; 95% CI=−2.19 to −0.23; P=0.02), with no increase in nausea and vomiting (risk ratio=0.68; 95% CI=0.42-1.10; P=0.11), and headache (risk ratio=0.96; 95% CI=0.44-2.09; P=0.92).

Conclusions: Etoricoxib can substantially reduce pain intensity in patients with laparoscopic cholecystectomy.

Departments of *Aneshesiology

ICU, ChongQing Traditional Chinese Medicine Hospital, Jiangbei District, Chongqing, China

The authors declare no conflicts of interest.

Reprints: Ronglan Qu, PhD, No.6, Panxi Road, Jiangbei District, Chongqing 400021, China (e-mail: 429865873@qq.com).

Received October 7, 2018

Accepted November 26, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.